세계의 비소세포폐암 시장(2023-2030년)

Overview

Global Non Small-Cell Lung Cancer Market reached US$ 25.4 billion in 2022 and is expected to reach US$ 47.4 billion by 2030 growing with a CAGR of 8.4% during the forecast period 2023-2030. The non-small-cell lung cancer market is driven by factors such as increasing incidence, advancements in research and development, personalized medicine, pipeline developments, and government initiatives.

The non-small-cell lung cancer treatment strategy is determined by the cancer's stage, which reflects how far along it has progressed. Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy are all possible forms of treatment. The selection of a course of treatment is impacted by a number of variables, including the size and location of the tumor, whether it has progressed to surrounding lymph nodes or distant regions of the body, and the patient's general condition.

Market Dynamics

The Increasing FDA Approval for Non-Small-Cell Lung Cancer Treatment is Driving the Global Non-Small-Cell Lung Cancer Market Growth

In August 2022, for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food and Drug Administration has given capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) regular approval for this diseases.

In addition, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line Treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who do not have EGFR, ALK, or ROS1 aberrations.

Patients must either have locally or metastatically advanced tumors that are not amenable to definitive chemoradiation or surgical excision. This combination may be used to treat patients regardless of histology or PD-L1 expression.

The Increasing Research Activities are Driving The Global Non-Small-Cell Lung Cancer Market Growth

In July 2023, the TROP2-directed antibody drug combination developed by AstraZeneca and Daiichi Sankyo showed a statistically significant increase in progression-free survival compared to conventional chemotherapy in previously treated locally progressed or metastatic illness in the first Phase III data.

Datopotamab deruxtecan (Dato-DXd) showed a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy, according to encouraging high-level findings from the TROPION-Lung01 Phase III trial.

There was an early tendency in favor of datopotamab deruxtecan versus docetaxel for the dual primary endpoint of overall survival (OS), but it did not reach the predetermined level of statistical significance at this interim analysis because the data were not mature. The experiment will proceed as scheduled to evaluate OS at a more mature stage.

Side Effects Associated with Non-Small-Cell Lung Cancer Therapy are Hampering the Global Non-Small-Cell Lung Cancer Market Growth

Side effects associated with non-small-cell lung cancer therapy restraining the market growth. Adverse immune-mediated reactions, which can be serious or lethal, can happen in any organ system or tissue and can influence many bodily systems at once. Pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic responses, solid organ transplant rejection, and difficulties from allogeneic hematopoietic stem cell transplantation are a few examples of immune-mediated adverse reactions that can happen at any moment during or after therapy with KEYTRUDA.

Additionally, serious or fatal infusion-related responses to KEYTRUDA are possible. When given to a pregnant woman, KEYTRUDA has the potential to harm the fetus due to its mode of action.

Segment Analysis

The global non-small-cell lung cancer market is segmented based on type, treatment, end-user and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 45.1% of the non-small-cell lung cancer market in 2022. Surgery is still the most common form of treatment for people with stage IB, stage II, and stage IIIA non-small cell lung cancer, despite the fact that there have been numerous advancements for patients with metastatic disease.

The U.S. Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent in January 2023 for adjuvant Treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimeters [cm]), II, or IIIA non-small cell lung cancer (NSCLC).

Geographical Penetration

North America Holds a Dominant Position in the Global Non-Small-Cell Lung Cancer Market

North America is estimated to hold around 38.3% of the total market share throughout the forecast period. Lung cancer is the second most prevalent cancer to be diagnosed globally. With 81% of all lung cancer diagnoses in the US being NSCLC, it is the most prevalent kind of disease. Lung cancer will be discovered in 238,340 adults in the United States in 2023 (117,550 men and 120,790 women). In 2020, there will likely be 2,206,771 lung cancer diagnoses worldwide. Both NSCLC and small cell lung cancer are included in these statistics.

Black and White women currently experience lower incidence rates than men. Black males are 12% more likely than White men to have lung cancer, which is the group with the highest lung cancer rates. Lung cancer is 16% less likely to affect Black women than White women. Lung cancer risk rises with advancing age. Approximately 53% of those with the condition are 70 years of age or older, according to estimates. People 65 and older are thought to be the target audience for 83% of diagnoses. While the majority of cases in women are discovered between the ages of 75 and 79, men are most likely to be diagnosed with NSCLC between the ages of 80 and 84.

Competitive Landscape

The major global players in the market include: Eli Lilly and Company, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, and Astellas among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the non-small-cell lung cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Clinical trials and research projects linked to NSCLC treatments could be affected if the conflict affects healthcare institutions and services. The creation of novel treatments could be slowed down by research pauses or interruptions.

Geopolitical unpredictability may cause a decline in international investments, especially those in the healthcare sector. This might have an effect on the amount of money allocated to NSCLC research, development, and infrastructure.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the non-small-cell lung cancer market to improve various aspects of data analysis. Radiologists can use AI algorithms to help them analyze CT and X-ray scan data to look for patterns and abnormalities that can indicate NSCLC. These algorithms can aid in enhancing the speed and accuracy of diagnosis. In addition, medical images of lung tumors and lesions can be segmented using AI to provide a more thorough understanding of their size, shape, and location. Planning and monitoring treatments need the use of this information.

By Drug Class

• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• Anaplastic Lymphoma Kinase (ALK) Inhibitors
• ROS1 Inhibitors
• BRAF Inhibitors
• Others

By Type

• Squamous Cell Carcinoma
• Large Cell Carcinoma
• Adenocarcinoma
• Others

By Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By End-user

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

UK

France

Italy

Spain

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In December 2022, the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), and pioneering pharmaceutical technology company XtalPi, announced a strategic partnership to find new Treatment options for non-small cell lung cancer (NSCLC).

Why Purchase the Report?

• To visualize the global non-small-cell lung cancer market segmentation based on the type, treatment, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of non-small-cell lung cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global non-small-cell lung cancer market report would provide approximately 61 tables, 69 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Type
• 3.3. Snippet by Treatment
• 3.4. Snippet by End-user
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with non-small-cell lung cancer
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing research activities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Drug Class

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.1.2. Market Attractiveness Index, By Drug Class
• 9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
• 9.4. ROS1 Inhibitors
• 9.5. BRAF Inhibitors
• 9.6. Others

10. By Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.1.2. Market Attractiveness Index, By Type
• 10.2. Squamous Cell Carcinoma*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Large Cell Carcinoma
• 10.4. Adenocarcinoma
• 10.5. Others

11. By Treatment

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 11.1.2. Market Attractiveness Index, By Treatment
• 11.2. Chemotherapy*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Targeted Therapy
• 11.4. Immunotherapy

12. By End-user

• 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
• 12.1.2. Market Attractiveness Index, By End-user
• 12.2. Hospitals*
  • 12.2.1. Introduction
  • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 12.3. Homecare
• 12.4. Specialty Clinics
• 12.5. Others

13. By Region

• 13.1. Introduction
  • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 13.1.2. Market Attractiveness Index, By Region
• 13.2. North America
  • 13.2.1. Introduction
  • 13.2.2. Key Region-Specific Dynamics
  • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.2.7.1. U.S.
    • 13.2.7.2. Canada
    • 13.2.7.3. Mexico
• 13.3. Europe
  • 13.3.1. Introduction
  • 13.3.2. Key Region-Specific Dynamics
  • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.3.7.1. Germany
    • 13.3.7.2. U.K.
    • 13.3.7.3. France
    • 13.3.7.4. Italy
    • 13.3.7.5. Spain
    • 13.3.7.6. Rest of Europe
• 13.4. South America
  • 13.4.1. Introduction
  • 13.4.2. Key Region-Specific Dynamics
  • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.4.7.1. Brazil
    • 13.4.7.2. Argentina
    • 13.4.7.3. Rest of South America
• 13.5. Asia-Pacific
  • 13.5.1. Introduction
  • 13.5.2. Key Region-Specific Dynamics
  • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 13.5.7.1. China
    • 13.5.7.2. India
    • 13.5.7.3. Japan
    • 13.5.7.4. Australia
    • 13.5.7.5. Rest of Asia-Pacific
• 13.6. Middle East and Africa
  • 13.6.1. Introduction
  • 13.6.2. Key Region-Specific Dynamics
  • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. Competitive Landscape

• 14.1. Competitive Scenario
• 14.2. Product Benchmarking
• 14.3. Company Share Analysis
• 14.4. Key Developments and Strategies

15. Company Profiles

• 15.1. Eli Lilly and Company*
  • 15.1.1. Company Overview
  • 15.1.2. Product Portfolio and Description
  • 15.1.3. Financial Overview
  • 15.1.4. Key Developments
• 15.2. Sanofi
• 15.3. Novartis AG
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Merck & Co., Inc.
• 15.6. Pfizer Inc.
• 15.7. AstraZeneca
• 15.8. Boehringer Ingelheim
• 15.9. Bristol-Myers Squibb Company
• 15.10. Astellas

LIST NOT EXHAUSTIVE

16. Appendix

• 16.1. About Us and Services
• 16.2. Contact Us